Anagram Therapeutics Inc.
PrivateLast Round
Early Funding
May 7, 2026
Total Funding Raised
$251.8M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Anagram Therapeutics Inc. operates in Healthcare & Life Sciences and is based in Framingham, Massachusetts. Its latest recorded funding round was an Early Funding round in May 2026.
Anagram Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel, orally delivered enzyme therapeutics for the treatment of serious diseases caused by malabsorption syndromes and nutrient metabolism disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B2C
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Anagram Therapeutics Inc. Comparables
Compare Anagram Therapeutics Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nestlé | 74% | |
| AbbVie | 72% | |
| Chiesi Farmaceutici S.p.A. | 69% |
For institutional investors. Book with your work email.
Anagram Therapeutics Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | May 7, 2026 | ||||
| Grant | Apr 4, 2023 | ||||
| Grant | Sep 10, 2021 | ||||
| Grant | Feb 12, 2020 | ||||
| VC Round | Jun 29, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Anagram Therapeutics Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NIH RADx | Grant |
| Cystic Fibrosis Foundation | Early Funding, Grant |
| Blackstone Life Sciences | Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 13, 2026
Open roles increased to 16, representing 44% of headcount.
- Jun 22, 2026
Open roles increased to 4, 2.7x the trailing average.
For institutional investors. Book with your work email.
Anagram Therapeutics Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Anagram Therapeutics Inc.'s valuation, stock price, and market status.
Is Anagram Therapeutics Inc. a public or private company?
Anagram Therapeutics Inc. is a private company.
What is the current stock price of Anagram Therapeutics Inc.?
Anagram Therapeutics Inc. is a private company, so its shares have no public market price. Caplight tracks Anagram Therapeutics Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Anagram Therapeutics Inc. worth (valuation)?
Valuation information for Anagram Therapeutics Inc. is not publicly available.
Can I buy Anagram Therapeutics Inc. stock?
Anagram Therapeutics Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Anagram Therapeutics Inc.'s last funding round?
Anagram Therapeutics Inc.'s most recent funding round was Early Funding on May 7, 2026.
Who are the main investors in Anagram Therapeutics Inc.?
Key investors in Anagram Therapeutics Inc. include NIH RADx, Cystic Fibrosis Foundation, Blackstone Life Sciences.
Will Anagram Therapeutics Inc. IPO soon?
No public IPO plans have been announced for Anagram Therapeutics Inc..
How can I track Anagram Therapeutics Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Anagram Therapeutics Inc.'s shares on secondary markets.